World-class leader in community-based oncology research.
Numbers at-a-glance
1,300+
oncology physicians providing access to clinical trials across multiple tumor types in SCRI’s research network
200+
locations across 20 states in the U.S., reaching 1 in 5 patients with cancer
700+
clinical trials actively enrolling patients
~3,400
patients participating in treatment trials each year
850+
first-in-human clinical trials conducted to date since SCRI’s inception
1,300+
oncology physicians providing access to clinical trials across multiple tumor types in SCRI’s research network
200+
locations across 20 states in the U.S., reaching 1 in 5 patients with cancer
700+
clinical trials actively enrolling patients
~3,400
patients participating in treatment trials each year
850+
first-in-human clinical trials conducted to date since SCRI’s inception
Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. As a leader in drug development, SCRI is at the forefront of bringing cutting-edge therapies to community clinicians and patients close to home.
We offer:
- End-to-end clinical trial site management all in one place – from our contract research organization (CRO) SCRI Development Innovations
- Centralized clinical trial support services through our site management organization (SMO)
- Personalized Medicine program that transforms real-world data into actionable insights
- Services to improve clinical trial diversity and access
Our academically-trained clinical researchers are key opinion leaders in oncology and experts in their disease sites. They serve as investigators for clinical trials across various solid tumor and hematologic malignancies, provide expertise across SCRI’s research network in the U.S. and connect via SCRI’s executive disease site research committees.
Since its inception, SCRI has partnered with leading biopharmaceutical companies to conduct community-based clinical research in oncology – from early to late-stage clinical trial development – in hundreds of communities across the U.S. We have contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA. Our expansive research network reaches 1 in 5 patients with cancer in the U.S. through our affiliated sites and brings together more than 1,300 oncology physicians who are actively enrolling patients into clinical trials at more than 200 locations across 20 states in the U.S. We provide access to more than 700 active clinical trials.
Since its inception, SCRI has partnered with leading biopharmaceutical companies to conduct community-based clinical research in oncology – from early to late-stage clinical trial development – in hundreds of communities across the U.S. We have contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA. Our expansive research network reaches 1 in 5 patients with cancer in the U.S. through our affiliated sites and brings together more than 1,300 oncology physicians who are actively enrolling patients into clinical trials at more than 200 locations across 20 states in the U.S. We provide access to more than 700 active clinical trials.
We help biopharma partners accelerate drug development and enhance clinical trial delivery.
Our biopharma partners benefit from Accelero, our accelerated operations model, which maximizes all functions of SCRI to accelerate drug development and optimize clinical trial delivery. Coordinated through our contract research organization (CRO), SCRI Development Innovations, Accelero enhances connectivity to SCRI research sites.
Through Accelero, SCRI Development Innovations collaborates with our Site Management Organization (SMO) and trial sites to maximize site contributions and efficiencies, accelerate activation timelines and study delivery, and synchronize end-to-end clinical research management through:
- Protocol design and feedback
- Early site engagement
- Abbreviated feasibility
- Enhanced start-up
- Enhanced enrollment support
- Patient matching through Personalized Medicine program
- E2E technology
By efficiently expanding access to clinical research in the community, we help our partners achieve their goal of bringing new oncology therapies to patients close to home.
